Common Elements Treatment Approach HIV Alcohol Reduction Trial in Zambia
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Nov 15, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Common Elements Treatment Approach HIV Alcohol Reduction Trial in Zambia is studying how different types of therapy can help people living with HIV who also struggle with alcohol use and mental health issues. The trial will look at the effects of a short therapy session, a longer therapy session combined with a special treatment approach called CETA, and the usual care that people receive. The goal is to see which method works best to improve both alcohol use and HIV treatment outcomes.
To be eligible for this study, participants need to be at least 18 years old, living with HIV, and receiving care at the study site. They should also be experiencing issues with alcohol use and have some mental health concerns or a more severe alcohol use disorder. Participants will need to have started their HIV treatment at least six months ago and faced challenges with their treatment in the past year. Those who join the study will receive different types of therapy and support to help them manage their health better. It’s important to note that individuals who are actively suicidal or intoxicated, or who are involved in other conflicting studies, cannot participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age or older
- • Living with HIV
- • Receiving HIV care at study site
- • Hazardous alcohol use plus at least one mental health or other substance use comorbidity or moderate to severe alcohol use disorder regardless of comorbidity
- • 6 months since initiation of Antiretroviral Treatment (ART)
- • Suboptimal HIV care outcome based on at least 1 of the following occurences in the past year: Late (at least 14 days from scheduled) Antiretroviral Treatment (ART) drug pick up, HIV viral load (VL) above the limit of assay detection, or referral to enhanced adherence
- Exclusion Criteria:
- • Plan to relocate out of Lusaka in next 6 months
- • No access to a telephone
- • Actively suicidal or alcohol intoxication and in need of immediate care
- • Currently psychotic
- • Participating in another interventional study that would interfere with participation
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lusaka, , Zambia
Lusaka, , Zambia
Lusaka, , Zambia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials